Endocrinology - Global Cardiology Academy

1-16 of 26

Addressing Cardiovascular Risk in Prediabetes: Why Earlier Action Matters
Addressing Cardiovascular Risk in Prediabetes: Why Earlier Action Matters
Diabetes Discourse
Addressing Cardiovascular Risk in Prediabetes: Why Earlier Action Matters
John W. Ostrominski, MD, MPH
- John W. Ostrominski, MD, MPH
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Nephrology
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Peter Rossing, MD, DMSc
- Peter Rossing, MD, DMSc
Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence
Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence
Heart Matters
Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence
M. Melih Dogan, MD
- M. Melih Dogan, MD
Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk
Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk
Heart Matters
Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk
Scott D. Isaacs, MD FACP, FACE
- Scott D. Isaacs, MD FACP, FACE
The Long Road to an FCS Diagnosis
The Long Road to an FCS Diagnosis
On the Frontlines of Familial Chylomicronemia Syndrome
The Long Road to an FCS Diagnosis
Charles Turck, PharmD, BCPS, BCCCP; Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
- Charles Turck, PharmD, BCPS, BCCCP
- Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
Could It Be FCS? Recognizing the Diagnostic Clues
Could It Be FCS? Recognizing the Diagnostic Clues
On the Frontlines of Familial Chylomicronemia Syndrome
Could It Be FCS? Recognizing the Diagnostic Clues
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA; Zahid Ahmad, MD, FNLA
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
- Zahid Ahmad, MD, FNLA
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
On the Frontlines of Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome: Improving Recognition and Diagnosis
Steve Jackson, PharmD; Nivedita Patni, MD
- Steve Jackson, PharmD
- Nivedita Patni, MD
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Heart Matters
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Shelina Ramnarine, PhD; Payal Kohli, MD, FACC
- Shelina Ramnarine, PhD
- Payal Kohli, MD, FACC
Is It Familial or Multifactorial Chylomicronemia Syndrome?
Is It Familial or Multifactorial Chylomicronemia Syndrome?
On the Frontlines of Familial Chylomicronemia Syndrome
Is It Familial or Multifactorial Chylomicronemia Syndrome?
Steve Jackson, PharmD; Michael D. Shapiro
- Steve Jackson, PharmD
- Michael D. Shapiro
Supporting Whole-Body Health Through the Gut
Supporting Whole-Body Health Through the Gut
NutritionEdge
Supporting Whole-Body Health Through the Gut
Shelina Ramnarine, PhD; Terri DeNeui, DNP, APRN, ACNP-BC
- Shelina Ramnarine, PhD
- Terri DeNeui, DNP, APRN, ACNP-BC
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Heart Matters
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Brian P. McDonough, MD, FAAFP; Anu Lala, MD
- Brian P. McDonough, MD, FAAFP
- Anu Lala, MD
- Martha Gulati, MD, MS, FACC, FAHA
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Heart Matters
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Alexandria May, PharmD, BCPS; Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
- Alexandria May, PharmD, BCPS
- Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Richard E. Pratley, MD; David Cherney, MD, PhD
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart Matters
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Susan Davis
- Susan Davis
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Rajiv Agarwal, MBBS, MD, FASN, BRCU

Prev
1
2
Next

1/2